Abstract:Objective To analyze change and meaning of T cell immune globulin sticky protein molecules -3 (T cell immunoglobulin mucin molecule-3, Tim-3) and procedural death receptor-1 (programmed cell death protein-1, PD-1) on the surface of peripheral blood mononuclear cells (Human peripheral blood mononuclear cells, PBMCs) in patients with hepatitis B virus (hepatitis B virus, HBV) related liver disease. Methods From January 2017 to December 2017, 20 hepatitis B virus carriers, 30 chronic hepatitis B patients, 20 severe hepatitis B patients, 30 hepatitis B cirrhosis patients and 20 hepatitis B liver cancer patients were compared with 20 healthy subjects selected as the healthy control group, and the levels of Tim-3 and PD-1 on the surface of PBMCs in the peripheral blood of all subjects were tested. Results Levels of Tim-3 and PD-1 on PBMCs surface were the lowest in healthy control group, compared with those in hepatitis B virus carriers group, and the difference had no statistical significance (P?>?0.05). As the aggravating of illness, the levels of Tim - 3 and PD-1 on PBMCs surface increased, which was the highest in severe hepatitis B group and hepatitis B liver cancer group. The difference among the levels of Tim- 3 and PD-1 on PBMCs surface in other groups were statistically significant, compared with those in healthy group and hepatitis B virus carrier group (P?0.05); the expression levels of Tim-3 and PD-1 on the PBMCs surface of patients with HBV infection were negatively correlated with the DNA load of HBV (r?=?-0.431, -0.422, P?0.05), and positively correlated with ALT and AST levels (r?=?0.214, 0.325, 0.234 and 0.354, P?0.05); there was a significant positive correlation between the expression level of Tim-3 and PD-1on the PBMCs surface of HBV infection patients (r?=?0.967, P?0.05). Conclusions The negative immune regulatory factors Tim-3 and PD-1 are key factors for the occurrence of liver inflammation and fibrosis in HBV-related liver diseases, and the regulation of Tim-3 and PD-1 level may provide a new idea for clinical immunotherapy.